SCHEMBL6802346

SCHEMBL6802346

COc1ccc(CC(C)(C)CC=O)c(Br)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.38
HTR2A P28223 3/20 0.37
HTR2C P28335 2/20 0.37
ALDH1A1 P00352 2/20 0.36
OPRD1 P41143 1/20 0.35
ERN1 O75460 1/20 0.35
TRIM24 O15164 1/20 0.35
TYR P14679 1/20 0.35
TRIM33 Q9UPN9 1/20 0.35
POLB P06746 1/20 0.34
CYP2A6 P11509 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
MMP1 P03956 1/20 0.33
MMP9 P14780 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805494 0.81 APLNR (0.40) APLNRHTR2AHTR2CALDH1A1ERN1
SCHEMBL2310172 0.77 APLNR (0.44) APLNRHTR2AHTR2CALDH1A1OPRD1
SCHEMBL6800561 0.73 SMN1; SMN2 (0.40) ALDH1A1POLBMTNR1AMTNR1BHSD17B10
SCHEMBL3484107 0.73 APLNR (0.46) APLNRHTR2AHTR2CPOLBCYP2A6
SCHEMBL6805614 0.71 ERN1 (0.35) ALDH1A1ERN1MTNR1AMTNR1BHSD17B10
SCHEMBL7674877 0.71 APLNR (0.44) APLNRHTR2AHTR2CALDH1A1POLB
Ammonia Solution, Strong SCHEMBL10346000 0.71 APLNR (0.44) APLNRHTR2AHTR2CPOLBCYP2A6
SCHEMBL3928795 0.69 ALDH1A1 (0.41) APLNRHTR2AHTR2CALDH1A1ERN1
SCHEMBL30486651 0.69 APLNR (0.46) APLNRHTR2AHTR2CPOLBCYP2A6
SCHEMBL3527192 0.69 APLNR (0.46) APLNRHTR2AHTR2CPOLBCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043994-A1 Gem-substituted alpha v beta 3 antagonists PHARMACIA CORPORATION 2004-03-04 US disclosed
EP-1313705-A1 GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS Pharmacia Corporation (US) 2003-05-28 EP disclosed
US-6531494-B1 Gem-substituted αvβ3 antagonists PHARMACIA CORPORATION 2003-03-11 US disclosed
WO-2002018340-A1 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS PHARMACIA CORPORATION (US) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043994-A1 Gem-substituted alpha v beta 3 antagonists CACNG5, ITGAV, ITGA5 APLNR 1886/4885HTR2A 3478/4885HTR2C 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.